CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 13 No. 8 2
12 years of randomized trials to be studied 

Meta-analysis to Examine Effect of Amifostine on Survival in Radiotherapy-Treated Patients

By Program Chairman
Walter J. Curran, Jr., MD
Kimmel Cancer Center of Jefferson Medical College, Philadelphia | August 1, 2004

VILLEJUIF, FRANCE- After more than 25 randomized trials, the effect of amifostine(Drug information on amifostine) (Ethyol) on the survival of patients treated with radiotherapy is still unknown. This is because most of the trials were neither designed nor powered to detect small survival differences and had followup periods that were either short (less than 2 years) or very short (a few months), according to Jean Bourhis, MD, PhD, of the departments of biostatistics and radiotherapy, Institut Gustave-Roussy, Villejuif, France. To assess whether this drug is associated with a survival benefit in radiotherapytreated patients, he and his col- leagues are conducting a metaanalysis of amifostine trials. Nonmetastatic Ca Only
Selection criteria include properly randomized trials performed between 1990 and June 2002, in which patients were randomized to receive radiotherapy or chemoradiotherapy plus amifostine, or to radiotherapy or chemoradiotherapy without amifostine. Patients had nonmetastatic head and neck, lung, or pelvic carcinomas. Updated data are being collected for all randomized patients from published and unpublished trials, and extensive checking and validation will be done to ensure the integrity of randomization and foloni low-up. Dr. Bourhis noted "pseudorandomization" might happen in some clinical trials. Tumor Control an Endpoint
The primary endpoint of the meta-analysis is the effect of amifostine on survival. The secondary endpoint is effect on tumor control. The meta-analysis will include more than 2,000 patients from 8 trials of non-small-cell lung cancer, 13 of head and neck cancer, and 7 of pelvic cancer. The investigators expect to report results in about 1 year. Dr. Bourhis's decision to include unpublished trials evoked some questions during the discussion period. "We are trying to avoid publication bias in favor of positive trials," he said. "We have to be careful not to avoid trials that have not been published because the results were not exactly as expected."

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





The 4th International Cytoprotection Investigators' Congress


 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • Skin Lesions
  • “This Is My Last Day on Earth”
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
  • Staying Fit Could Ward Off Lung and Colorectal Cancer for Middle-Age Men
  • Obesity Impairs Efficacy of L-Asparaginase in Leukemia Treatment
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy